Right there is the one wild card. The patients chosen are not necessarily all the same in terms of disease. Before the first group of 4 patients were all fairly similar as "end stage". These 18 patients may be quite dissimilar, so some may benefit more than others. I do think some quite different responses are possible, but I have no knowledge of the patient selection. I do trust in the team to have done it carefully.
Passing Through the 20's, page-120
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
